According to this, we further applied a broad-spectrum anti-tumor drug Doxorubicin and found that MINA53 knockdown sensitized glioblastoma cells to Doxorubicin, suggesting that MINA53 could be a potential therapy target for glioblastoma. This evidence concerns the gene RIOX2 and neoplasm.